Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Pharmaceutical Zhongxi Pharmaceutical Co., Ltd [1][2]. Group 1: Drug Information - Drug Name: Amisulpride Orally Disintegrating Tablets - Dosage Form: Tablet - Specifications: 50mg, 0.2g - Registration Classification: Chemical Drug - Approval Numbers: National Drug Approval Code H20250041, H20250042 - Approval Conclusion: Change of marketing authorization holder from "Shanghai Zezheng Pharmaceutical Technology Co., Ltd." to "Shanghai Pharmaceutical Zhongxi Pharmaceutical Co., Ltd." [2]. Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is an improved formulation of Amisulpride Tablets, which was launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [3]. - As of the date of the announcement, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [4]. - According to IQVIA data, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [5]. Group 3: Company Impact - The change in marketing authorization holder for Amisulpride Orally Disintegrating Tablets enhances the product line of Shanghai Pharmaceuticals and is expected to improve the company's market competitiveness [6].

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of a change in the marketing authorization holder for Amisulpride orally disintegrating tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received the approval from the National Medical Products Administration for the change of marketing authorization holder [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] Group 1: Company Developments - The marketing authorization holder for Amisulpride Orally Disintegrating Tablets has been officially changed to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] - The company submitted the registration application for the change of marketing authorization holder to the National Medical Products Administration in September 2025, which has been accepted [1] - The company has invested approximately 31.5 million yuan in the development of this drug as of the date of the announcement [1] Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd. (referred to as "Shiyou"), has received the approval notice from the National Medical Products Administration for the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou [1] Group 1 - The approval notice includes notification numbers: 2025B04804 and 2025B04815 [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於子公司成為氨磺必利口崩片上市許可持有人的公 告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 证券代码：601607 证券简称：上海医药 编号：临 2025-093 上海医药集团股份有限公司 关于子公司成为氨磺必利口崩片上市许可持有人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

证券代码：601607 证券简称：上海医药 编号：临 2025-093 上海医药集团股份有限公司 关于子公司成为氨磺必利口崩片上市许可持有人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药中西制药有限公司（以下简称"上药中西"）收到国家药品监督管理 局（以下简称"国家药监局"）颁发的《药品补充申请批准通知书》（通知书编 号：2025B04804、2025B04815），其同意将氨磺必利口崩片（以下简称"该药 品"）上市许可持有人变更为上海上药中西制药有限公司。 一、该药品的基本情况 药品名称：氨磺必利口崩片 二、该药品的相关信息 氨磺必利口崩片是赛诺菲（Sanofi）公司于 1986 年在法国上市的氨磺必利 片的改良剂型，用于治疗成人精神分裂症。2025 年 9 月，上药中西就该药品上 市许可持有人变更向国家药监局提出注册上市申请并获受理。截至本公告日，公 司针对该药品已投入约人民币 3,150 万元。 截至本公告日，中国境内氨磺必利口 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Pharmaceuticals Zhongxi Pharmaceutical Co., Ltd. This move is expected to enhance the company's product line and market competitiveness [1]. Group 1 - The National Medical Products Administration issued a "Drug Supplement Application Approval Notice" allowing the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1]. - Amisulpride Orally Disintegrating Tablets is an improved formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1]. - The change in marketing authorization holder to Shanghai Pharmaceuticals Zhongxi is anticipated to enrich the company's product offerings and strengthen its competitive position in the market [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. (referred to as "Shiyou Zhongxi"), has received a notification from the National Medical Products Administration (NMPA) approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shiyou Zhongxi [1] Group 1 - The NMPA has granted approval for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1] - Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - Shiyou Zhongxi submitted the registration application for the change of marketing authorization holder to the NMPA in September 2025, which has been accepted [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Group 1 - The Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were originally launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [1] - The application for the change of marketing authorization holder was submitted to the National Medical Products Administration in September 2025 and has been accepted [1]

Economic Overview - Shanghai's GDP for the first three quarters reached 40,721.17 billion yuan, with a year-on-year growth of 5.5% [1] - The industrial production maintained a growth trend, with the industrial added value increasing by 5.2% year-on-year [2] Industrial Performance - The total industrial output value for large-scale industries in Shanghai grew by 5.7% year-on-year, with an acceleration of 0.1 percentage points compared to the first half of the year [2] - Key sectors such as railway, shipbuilding, aerospace, and other transportation equipment manufacturing saw a significant increase of 15.9% [2] - Electrical machinery and equipment manufacturing grew by 14.3%, while computer, communication, and other electronic equipment manufacturing increased by 12.1% [2] Investment Trends - Industrial investment in Shanghai rose by 20.3%, outpacing the overall fixed asset investment growth rate of 14.3 percentage points [2] - The resilience and internal driving force of industrial growth have been enhanced, indicating a positive investment outlook for future production [2] Emerging Industries - The three leading industries in Shanghai experienced an 8.5% increase in output value, surpassing the overall industrial growth by 2.8 percentage points [3] - The artificial intelligence manufacturing sector grew by 12.8%, and integrated circuit manufacturing increased by 11.3% [3] - High-tech manufacturing output value rose by 10.3%, with aerospace and communication equipment manufacturing growing by 20.6% and 13.4%, respectively [3] Strategic Initiatives - Shanghai is focusing on enhancing its artificial intelligence industry by aiming for a tripling of innovative enterprises, industry scale, and talent [4] - The city has established 12 national-level intelligent factories and 254 advanced intelligent factories, leading the nation in smart manufacturing [4] - In the biopharmaceutical sector, Shanghai's industry scale is expected to exceed 1 trillion yuan this year, with significant advancements in innovative drug approvals [5] Future Industry Development - Shanghai aims to cultivate a number of future industry clusters and lead in disruptive technologies by 2027 [5] - The city plans to nurture around 20 leading enterprises in future industries and establish itself as a globally influential hub by 2030 [5]